Biopharmx (NYSEAMERICAN:BPMX) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.02) by $0.01, Fidelity Earnings reports. The firm had revenue of $0.01 million for the quarter.

Shares of Biopharmx stock remained flat at $$0.10 on Friday. 4,958,340 shares of the stock traded hands, compared to its average volume of 4,486,990. Biopharmx has a 12 month low of $0.05 and a 12 month high of $0.33.

TRADEMARK VIOLATION WARNING: “Biopharmx (BPMX) Announces Earnings Results, Beats Estimates By $0.01 EPS” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at

Biopharmx Company Profile

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).

Featured Article: Cryptocurrencies

Earnings History for Biopharmx (NYSEAMERICAN:BPMX)

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with's FREE daily email newsletter.